Live news related to UCB stock (BE0003739530): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
UCB announced on Wednesday the completion of its acquisition of Candid Therapeutics, a clinical-stage biotech specializing in T-cell engaging therapie…
UCB presented new mechanistic data on Cimzia (certolizumab pegol) at EULAR 2026 on Friday, showing that its lack of an Fc domain allows it to maintain…
UCB laboratories disclosed on Wednesday Phase 2/3 data and their open-label extensions regarding Bimzelx (bimekizumab) in the treatment of psoriatic a…
UCB announced on Tuesday the complete acquisition of Neurona Therapeutics and its drug candidate Rezanecel, a Phase I/II treatment for drug-resistant …
UCB announced on Tuesday its research on thymidine kinase 2 deficiency (TK2d), an ultra-rare disease, at the EUROMIT 2026 conference. The data highlig…
UCB and Biogen announced on Monday the publication in The Lancet of the phase 3 results of dapirolizumab pegol (DZP) in the treatment of systemic lupu…
UCB announced on Tuesday data from the BE BOLD trial confirming the clinical superiority of Bimzelx (bimekizumab) over Skyrizi (risankizumab) in the t…
UCB SA has announced the convening of its ordinary and extraordinary general meeting on April 30, 2026. The pharmaceutical group will submit for share…
TD Cowen établit une recommandation à l'achat sur UCB et relève son objectif de cours à 310 €.
Morgan Stanley revoit à la baisse sa position sur le titre UCB ce vendredi 6 mars 2026.
